Drug Profile

NEXI 002

Alternative Names: NEXI-002

Latest Information Update: 02 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NexImmune
Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Multiple myeloma

Most Recent Events

17 Nov 2022 NexImmune terminates phase I/II trial in Multiple myeloma in USA due to lack of accrual (NCT04505813)
12 Dec 2021 Preliminary efficacy, safety and pharmacokinetics data from a phase I/II trial in Multiple myeloma released by NexImmune
11 Dec 2021 Updated adverse events data from a phase I trial in Multiple myeloma presented at the 63^rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com